About Biotec Pharmacon
Biotec Pharmacon ASA develops new pharmaceutical products for treatment of immune related diseases. The company’s bioactive compound SBG (SBG, soluble beta-1,3/1,6-glucan) has completed clinical phase III studies within two therapeutic indications; treatment of diabetic ulcers and prevention and treatment of oral mucositis. However, these trials did not show positive effect as anticipated. It seems to be caused by an unexpected interaction between SBG and the container material.
The company’s clinical development program also includes immunotherapy of cancer where combination treatment of SBG and monoclonal antibodies currently is in clinical phase I/II. Proof of concept trials with SBG in animals for treatment of Inflamatory Bowel Disease and treatment of Asthma have also started.
The subsidiary Biotec Marine Biochemicals AS develops and manufactures unique DNA/RNA-modifying marine enzymes for use in gene technology research and diagnostics.
Until late 2009 the company also marketed immune stimulating health products for the consumer market. This division has now been divested.
Biotec Pharmacon is listed on the Oslo Stock Exchange under the ticker “BIOTEC”.
News
- Svein Lien appointed new CEO of Biotec Pharmacon ASAMarch 10,2010Svein Lien has been appointed new CEO of Biotec Pharmacon, following Lars Viksmoen’s decision to resign after 3 years as CEO. Svein Lien will assume the position with effect from 15 March, 2010.
- Biotec Pharmacon presenting re-established platform at BIO-Europe 2010March 09,2010Dr Sven Rohmann presented on behalf of Biotec Pharmacon at BIO-Europe Spring 2010 in Barcelona. The presentation took place at March 9, 12:30, under the AutoImmune/Inflammation Section.
- Testing SBG packaging containers after weak results from oral mucositis study February 22,2010Biotec Pharmacon has received data showing that SBG failed to show superiority over placebo in the phase III study for oral mucositis. Newly available biological activity assays indicate that SBG used in the diabetic ulcer program may have been inactivated as a result of interaction with polyethylene in the product containers. The company plans to carry out accelerated stability studies of SBG with alternative containers.